Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatic patients: a cross sectional study

BMC Pulmonary Medicine

Marcus B Conde¹  Patricia RM Rocco⁴  Ronir R Luiz²  Karen S Azevedo³ 

[1]Institute of Thoracic Diseases, Federal University of Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, 255/6º andar, Cidade Universitária, CEP 21941–913, Rio de Janeiro, Brazil

[2]Institute of Public Health Studies, Federal University of Rio de Janeiro, Praça Jorge Machado Moréia 100, Cidade Universitária, CEP 21941-598, Rio de Janeiro, Brazil

[3]Laboratory of Pulmonary Function Tests, Institute of Thoracic Diseases, Federal University of Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, 255/3º andar/03 F91, Cidade Universitária, CEP 21941-913, Rio de Janeiro, Brazil

[4]Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Cidade Universitária - CCS, CEP 21941-902, Rio de Janeiro, Brazil

关键词: Bronchodilator response;    Asthma;    Hyperinflation;    Air trapping;    Vital capacity;   

Others  :  1161070
DOI  :  10.1186/1471-2466-12-49

 received in 2011-11-29, accepted in 2012-08-23,  发布年份 2012

【 摘 要 】

Background

Bronchodilator response in patients with asthma is evaluated based on post-bronchodilator increase in forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC). However, the need for additional parameters, mainly among patients with severe asthma, has already been demonstrated.

Methods

The aim of this study was to evaluate the usefulness of vital capacity (VC) and inspiratory capacity (IC) to evaluate bronchodilator response in asthma patients with persistent airflow obstruction. The 43 asthma patients enrolled in the study were stratified into moderate or severe airflow obstruction groups based on baseline FEV₁. All patients performed a 6-minute walk test before and after the bronchodilator (BD). A bipolar visual analogue scale post-BD was performed to assess clinical effect. The correlation between VC and IC and clinical response, determined by visual analogue scale (VAS) and 6-minute walk test (6MWT), was investigated.

Results

Patients in the severe group presented: 1) greater bronchodilator response in VC (48% vs 15%, p = 0.02), 2) a significant correlation between VC variation and the reduction in air trapping (Rs = 0.70; p < 0.01), 3) a significant agreement between VC and VAS score (kappa = 0.57; p < 0.01). There was no correlation between IC and the reduction in air trapping or clinical data.

Conclusions

VC may be a useful additional parameter to evaluate bronchodilator response in asthma patients with severe airflow obstruction.

【 授权许可】

   
2012 Azevedo et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. NHLBI / WHO Workshop Report. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD; 2009.
• [2]Pellegrino R, Viegi G, Brusasco RO, Crapo R, Burgos F, Casaburi R, Coates A, Van Der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, Macintyre N, Mckay R, Miller MR, Navajas D, Pederson OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-68.
• [3]O’Donnell DE, Lam M, Webb KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:1557-1565.
• [4]Tantucci C, Duguet A, Similowski T, Zelter M, Derenne J-P, Milic-Emil J: Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998, 12:799-804.
• [5]Rodrigues JR, Pereira CAC: Resposta a broncodilatador na espirometria: que parâmetros e valores são clinicamente relevantes em doenças obstrutivas? J Pneumol 2000, 27:35-47.
• [6]O’Donnell DE, Forkert L, Webb KA: Evaluation of bronchodilator responses in patient with “irreversible” emphysema. Eur Respir J 2001, 18:914-920.
• [7]Paré PD, Lawson LM, Brooks LA: Patterns of response to inhaled bronchodilators in asthmatics. Am Rev Respir Dis 1993, 127:680-685.
• [8]Lougheed MD, Lam M, Forkert L, Webb KA, O’Donnell DE: Breathlessness during acute bronchoconstriction in asthma. Am Rev Repir Dis 1993, 148:1452-1459.
• [9]Tantucci C, Ellaffi M, Duguet A, Similowski T, Derenne J-P, Milic-Emili J: Dynamic hyperinflation and flow limitation during methacholine-induced bronchoconstriction in asthma. Eur Respir J 1999, 14:295-301.
• [10]Filippelli M, Duranti R, Gigliott F, Bianchi R, Grazzini M, Stendardi L, Scano G: Overall contribution of chest wall hyperinflation to breathlessness in asthma. Chest 2003, 124:2164-2170.
• [11]Lougheed MD, Fisher T, O’Donnell DE: Dynamic hyperinflation during bronchoconstriction in asthma. Chest 2006, 130:1072-1081.
• [12]Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, Curran-Everett D, Erzurun SC, Gaston BM, Israel E, Jarjour NN, Moore WC, Peters SP, Teague WG, Wenzel SE: Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008, 104:394-403.
• [13]Sutherland TJT, Cowan JO, Taylor DR: Dynamic hyperinflation with bronchoconstriction. Am J Respir Crit Care Med 2008, 177:970-975.
• [14]Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. NHLBI / WHO Workshop Report. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD; 2006.
• [15]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Van Der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, Macintyre N, Mckay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [16]Wanger J, Clausen J, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, Van Der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, Mckay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J 2005, 26:511-522.
• [17]Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B: Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725-734.
• [18]Polgar G, Promadhat V: Pulmonar function testing in children. Techniques and standards. WB Saunders Co, Philadelphia; 1971.
• [19]Goldman HI, Becklake MR: Respiratory Function Tests. Normal values at median altitudes and the prediction of normal results. Am Rev Tuberc Pulm Dis 1959, 79:457-467.
• [20]American Thoracic Society: ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
• [21]Noseda A, Schmerber J, Prigogine T, Yernault JC: Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J 1992, 5:1043-1053.
• [22]Newton MF, O’Donnell DE, Forkert L: Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002, 121:1042-1050.
• [23]Byrt T: How good is agreement. Epidemiology 1996, 7:561.
• [24]Chan YH: Biostatitics 104: Correlation analysis. Singapore Med J 2003, 44:614-619.
• [25]Barreiro E, Gea J, Sanjuás C, Marcos R, Broquetas J, Milic-Emili J: Dyspnoea at rest and at end of different exercises in patients with near-fatal asthma. Eur Respir J 2004, 24:219-225.
• [26]Isakovic J, Isakovic L, Filipovic I: The correlation between the Borg score and VAS and lung function parameters in patients with asthma and COPD. 20th Ann Cong of the European Respiratory Society (ERS), Barcelona, 18–22 sep2010 2010. [Eur Respir J] Suppl 54
• [27]Belman MJ, Warren C, Botnick C, Shin JW: Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:967-975.
• [28]O’Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:542-549.
• [29]Kosmas EN, Milic-Emili J, Polychronaki A, Dimitroulis I, Retsou S, Gaga M, Koutsoukou A, Roussos C, Koulouris NG: Exercise-induce flow limitation, dynamic hyperinflation and exercise capacity in patients with bronchial asthma. Eur Respir J 2004, 24:378-384.
• [30]Teeter JG, Bleecker ER: Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998, 11:272-277.
• [31]Wenzel S: Severe asthma in adults. Am J Respir Crit Care Med 2005, 172:149-160.
• [32]Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Communitu for steel and coal. Official statement of the European Respiratory Society. Eur Respir J 1993, 16:5-40.